Cardioprotective effects of rosuvastatin and carvedilol on delayed cardiotoxicity of doxorubicin in rats

References

• Abd Elbaky NA, Ali AA, Ahmed RA. 2010. Cardioprotective effect of simvastatin on doxorubicin-induced oxidative cardiotoxicity in rats. J Basic Appl Sci 6:29–38.
   Google Scholar
• Acar Z, Kale A, Turgut M, Demircan S, Durna K, Demir S, Meric M, Agac MT. 2011. Efficiency of atorvastatin in the protection of anthracycline-induced cardiomyopathy. J Am Coll Cardiol 58:988–989.
   PubMed Web of Science ®Google Scholar
• Anders RJ, Shanes JG, Zeller FP. 1986. Lower incidence of doxorubicin-induced cardiomyopathy by once-a-week low-dose administration. Am Heart J 111:755–759.
   Google Scholar
• Arozal W, Sari FR, Watanabe K, Arumugam S, Veeraveedu PT, Ma M, Thandavarayan RA, Sukumaran V, Lakshmanan AP, Kobayashi Y, Mito S, Soetikno V, Suzuki K. 2011. carvedilol-afforded protection against daunorubicin-induced cardiomyopathic rats in vivo: Effects on Cardiac Fibrosis and Hypertrophy. ISRN Pharmacol 2011:430–549.
   Google Scholar
• Arozal W, Watanabe K, Veeraveedu PT, Ma M, Thandavarayan RA, Sukumaran V, Suzuki K, Kodama M, Aizawa Y. 2010. Protective effect of carvedilol on daunorubicin-induced cardiotoxicity and nephrotoxicity in rats. Toxicology 274:18–26.
   Google Scholar
• Bardeleben RV, Dunkern T, Kaina B, Fritz G. 2002. The HMG-CoA reductase inhibitor lovastatin protects cells from the antineoplastic drugs doxorubicin and etoposide. Int J Mol Med 10:473–479.
   Google Scholar
• Cadeddu C, Piras A, Mantovani G, Deidda M, Dessì M, Madeddu C, Massa E, Mercuro G. 2010. Protective effects of the angiotensin II receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress, and early ventricular impairment. Am Heart J 160:487.e1–487.e7.
   Google Scholar
• Chatterjee K, Zhang J, Honbo N, Karliner JS. 2010. Doxorubicin cardiomyopathy. Cardiology 115:155–162.
   PubMed Web of Science ®Google Scholar
• Damrot J, Nübel T, Epe B, Roos WP, Kaina B, Fritz G. 2006. Lovastatin protects human endothelial cells from the genotoxic and cytotoxic effects of the anticancer drugs doxorubicin and etoposide. Br J Pharmacol 149:988–997.
   PubMed Web of Science ®Google Scholar
• Davignon J. 2004. Beneficial cardiovascular pleiotropic effects of statins. Circulation 109:III39–III43.
   PubMed Web of Science ®Google Scholar
• De Angelis A, Piegari E, Cappetta D, Marino L, Filippelli A, Berrino L, Ferreira-Martins J, Zheng H, Hosoda T, Rota M, Urbanek K, Kajstura J, Leri A, Rossi F, Anversa P. 2010. Anthracycline cardiomyopathy is mediated by depletion of the cardiac stem cell pool and is rescued by restoration of progenitor cell function. Circulation 121:276–292.
   PubMed Web of Science ®Google Scholar
• de Nigris F, Rienzo M, Schiano C, Fiorito C, Casamassimi A, Napoli C. 2008. Prominent cardioprotective effects of third generation beta blocker nebivolol against anthracycline-induced cardiotoxicity using the model of isolated perfused rat heart. Eur J Cancer 44:334–340.
   Google Scholar
• Iliskovic N, Singal PK. 1997. Lipid lowering: an important factor in preventing adriamycin-induced heart failure. Am J Pathol 150:727–734.
   PubMed Web of Science ®Google Scholar
• Kalay N, Basar E, Ozdogru I, Er O, Cetinkaya Y, Dogan A, Inanc T, Oguzhan A, Eryol NK, Topsakal R, Ergin A. 2006. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol 48:2258–2262.
   PubMed Web of Science ®Google Scholar
• Kawai K, Qin F, Shite J, Mao W, Fukuoka S, Liang CS. 2004. Importance of antioxidant and antiapoptotic effects of beta-receptor blockers in heart failure therapy. Am J Physiol Heart Circ Physiol 287:H1003–H1012.
   PubMed Web of Science ®Google Scholar
• Kleemann R, Princen HM, Emeis JJ, Jukema JW, Fontijn RD, Horrevoets AJ, Kooistra T, Havekes LM. 2003. Rosuvastatin reduces atherosclerosis development beyond and independent of its plasma cholesterol-lowering effect in APOE*3-Leiden transgenic mice: evidence for antiinflammatory effects of rosuvastatin. Circulation 108:1368–1374.
   PubMed Web of Science ®Google Scholar
• Lim CC, Zuppinger C, Guo X, Kuster GM, Helmes M, Eppenberger HM, Suter TM, Liao R, Sawyer DB. 2004. Anthracyclines induce calpain-dependent titin proteolysis and necrosis in cardiomyocytes. J Biol Chem 279:8290–8299.
   Google Scholar
• Martin JH, Krum H. 2007. Statins and clinical outcomes in heart failure. Clin Sci 113:119–127.
   Google Scholar
• Matsui H, Morishima I, Numaguchi Y, Toki Y, Okumura K, Hayakawa T. 1999. Protective effects of carvedilol against doxorubicin-induced cardiomyopathy in rats. Life Sci 65:1265–1274.
   PubMed Web of Science ®Google Scholar
• Mochizuki M, Yano M, Oda T, Tateishi H, Kobayashi S, Yamamoto T, Ikeda Y, Ohkusa T, Ikemoto N, Matsuzaki M. 2007. Scavenging free radicals by low-dose carvedilol prevents redox-dependent Ca2+ leak via stabilization of ryanodine receptor in heart failure. J Am Coll Cardiol 49:1722–1732.
   Google Scholar
• Noguchi N, Nishino K, Niki E. 2000. Antioxidant action of the antihypertensive drug, carvedilol, against lipid peroxidation. Biochem Pharmacol 59:1069–1076.
   PubMed Web of Science ®Google Scholar
• Oliveira PJ, Bjork JA, Santos MS, Leino RL, Froberg MK, Moreno AJ, Wallace KB. 2004. Carvedilol-mediated antioxidant protection against doxorubicin-induced cardiac mitochondrial toxicity. Toxicol Appl Pharmacol 200:159–168.
   PubMed Web of Science ®Google Scholar
• Otto A, Fontaine D, Fontaine J, Berkenboom G. 2005. Rosuvastatin treatment protects against nitrate-induced oxidative stress. J Cardiovasc Pharmacol 46:177–184.
   PubMedGoogle Scholar
• Ramasubbu K, Estep J, White DL, Deswal A, Mann DL. 2008. Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy. J Am Coll Cardiol 51:415–426.
   PubMed Web of Science ®Google Scholar
• Riad A, Bien S, Westermann D, Becher PM, Loya K, Landmesser U, Kroemer HK, Schultheiss HP, Tschöpe C. 2009. Pretreatment with statin attenuates the cardiotoxicity of Doxorubicin in mice. Cancer Res 69:695–699.
   PubMed Web of Science ®Google Scholar
• Robinson JG. 2008. Models for describing relations among the various statin drugs, low-density lipoprotein cholesterol lowering, pleiotropic effects, and cardiovascular risk. Am J Cardiol 101:1009–1015.
   PubMed Web of Science ®Google Scholar
• Santos DL, Moreno AJ, Leino RL, Froberg MK, Wallace KB. 2002. Carvedilol protects against doxorubicin-induced mitochondrial cardiomyopathy. Toxicol Appl Pharmacol 185:218–227.
   PubMed Web of Science ®Google Scholar
• Sharma H, Pathan RA, Kumar V, Javed S, Bhandari U. 2011. Anti-apoptotic potential of rosuvastatin pretreatment in murine model of cardiomyopathy. Int J Cardiol 150:193–200.
   Google Scholar
• Sicard P, Delemasure S, Korandji C, Segueira-Le Grand A, Lauzier B, Guilland JC, Duvillard L, Zeller M, Cottin Y, Vergely C, Rochette L. 2008. Anti-hypertensive effects of Rosuvastatin are associated with decreased inflammation and oxidative stress markers in hypertensive rats. Free Radic Res 42:226–236.
   PubMed Web of Science ®Google Scholar
• Spallarossa P, Garibaldi S, Altieri P, Fabbi P, Manca V, Nasti S, Rossettin P, Ghigliotti G, Ballestrero A, Patrone F, Barsotti A, Brunelli C. 2004. Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro. J Mol Cell Cardiol 37:837–846.
   PubMed Web of Science ®Google Scholar
• Steinherz LJ, Steinherz PG, Tan CT, Heller G, Murphy ML. 1991. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 266:1672–1677.
   PubMed Web of Science ®Google Scholar
• Strandberg TE. 2010. Lipid-lowering drugs and heart failure: where do we go after the statin trials? Curr Opin Cardiol 25:385–393.
   PubMed Web of Science ®Google Scholar
• Susic D, Varagic J, Ahn J, Slama M, Frohlich ED. 2003. Beneficial pleiotropic vascular effects of rosuvastatin in two hypertensive models. J Am Coll Cardiol 42:1091–1097.
   PubMed Web of Science ®Google Scholar
• Takemura G, Fujiwara H. 2007. Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. Prog Cardiovasc Dis 49:330–352.
   PubMed Web of Science ®Google Scholar
• van Dalen EC, Caron HN, Dickinson HO, Kremer LC. 2011. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev 15(6):CD003917.
   Google Scholar
• Yoshida M, Shiojima I, Ikeda H, Komuro I. 2009. Chronic doxorubicin cardiotoxicity is mediated by oxidative DNA damage-ATM-p53-apoptosis pathway and attenuated by pitavastatin through the inhibition of Rac1 activity. J Mol Cell Cardiol 47:698–705.
   PubMed Web of Science ®Google Scholar
• Yue TL, McKenna PJ, Ruffolo RR Jr, Feuerstein G. 1992. Carvedilol, a new beta-adrenoceptor antagonist and vasodilator antihypertensive drug, inhibits superoxide release from human neutrophils. Eur J Pharmacol 214:277–280.
   PubMed Web of Science ®Google Scholar
• Zhai Y, Gao X, Wu Q, Peng L, Lin J, Zuo Z. 2008. Fluvastatin decreases cardiac fibrosis possibly through regulation of TGF-beta(1)/Smad 7 expression in the spontaneously hypertensive rats. Eur J Pharmacol 587:196–203.
   PubMed Web of Science ®Google Scholar
• Zhou R, Xu Q, Zheng P, Yan L, Zheng J, Dai G. 2008. Cardioprotective effect of fluvastatin on isoproterenol-induced myocardial infarction in rat. Eur J Pharmacol 586:244–250.
   PubMed Web of Science ®Google Scholar